Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma By Ogkologos - March 3, 2025 99 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR Olive Oil Found to Reduce Risk of Death from Dementia, Cancer,... January 13, 2022 What to Know About 3 Common Misconceptions Around Food and Cancer... April 25, 2023 Worries About Medical Bills May Worsen Health Outcomes After Cancer Diagnosis March 13, 2021 Finally Pregnant After Struggling With Infertility For Years, She Was Diagnosed... October 25, 2019 Load more HOT NEWS New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations... EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of... Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age A new IARC live webinar on evidence in primary cancer prevention
